{"id":745303,"date":"2016-11-13T08:00:00","date_gmt":"2016-11-13T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/"},"modified":"2025-11-07T01:25:32","modified_gmt":"2025-11-07T06:25:32","slug":"merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/","title":{"rendered":"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection"},"content":{"rendered":"<p class=\"bwalignc\">       Phase 2 Data Presentations at The Liver Meeting <sup> \u00ae <\/sup>         Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients        for Whom Direct-Acting Antiviral Treatment Previously Failed     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the presentation of results from three Phase 2 clinical<br \/>\n      trials evaluating MK-3682B (MK-3682\/grazoprevir\/ruzasvir<sup>1<\/sup>),<br \/>\n      the company\u2019s investigational all-oral, triple-combination regimen for<br \/>\n      the treatment of chronic hepatitis C (HCV) infection (informally<br \/>\n      referred to as MK3). Results from Part B of <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=1&amp;md5=22db05e346a45883c00c3eaf1d2f69b8\" rel=\"nofollow\"><br \/>\n<i>C-CREST<br \/>\n      1<\/i><br \/>\n<\/a> &amp; <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=2&amp;index=2&amp;md5=c64a842629fb63ad58990a70acda02ff\" rel=\"nofollow\"><br \/>\n<i>2<\/i><br \/>\n<\/a><br \/>\n      demonstrated high rates of sustained virologic response<sup>2<\/sup><br \/>\n      (SVR) 12 weeks after the completion of therapy (SVR12, considered<br \/>\n      virologic cure) in patients with chronic HCV genotype (GT) 1 or GT3<br \/>\n      infection who received eight weeks of treatment with MK-3682B. Findings<br \/>\n      from <i>C-CREST 1<\/i> &amp; <i>2<\/i> Part B also demonstrated high rates<br \/>\n      of SVR12 in GT1, GT2 and GT3-infected patients who received MK3 for 12<br \/>\n      or 16 weeks. Findings from Part C of <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332707&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=C-CREST+1&amp;index=3&amp;md5=7942a778dc4c3023309b6f145a456531\" rel=\"nofollow\"><br \/>\n<i>C-CREST<br \/>\n      1<\/i><br \/>\n<\/a> &amp; <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02332720&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=2&amp;index=4&amp;md5=92c5ed3bb759eca1f31419d94f796821\" rel=\"nofollow\"><br \/>\n<i>2<\/i><br \/>\n<\/a><br \/>\n      and interim results from the ongoing <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02613403&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=C-SURGE&amp;index=5&amp;md5=787c2b0e4a4ee646430fe7183e073805\" rel=\"nofollow\"><br \/>\n<i>C-SURGE<\/i><br \/>\n<\/a><br \/>\n      study showed high rates of SVR12 and SVR8, respectively, in chronic HCV<br \/>\n      patients who had failed prior treatment with investigational or approved<br \/>\n      direct-acting antiviral regimens. These results will be announced in<br \/>\n      oral presentations at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aasld.org%2Fevents-professional-development%2Fliver-meeting&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE+2016&amp;index=6&amp;md5=0a815d8584a767abeff9110a3907b244\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup> 2016<\/a> today (<i>C-CREST 1 <\/i>&amp;<i> 2 <\/i>Parts<br \/>\n      B and C) and tomorrow (<i>C-SURGE<\/i>).\n    <\/p>\n<p>\n      \u201cAcross the chronic hepatitis C treatment landscape, incredible progress<br \/>\n      has been made in a remarkably short amount of time, but there remains a<br \/>\n      need for more options, particularly for patients who do not achieve<br \/>\n      sustained virologic response with treatment regimens available today,\u201d<br \/>\n      said Dr. Eliav Barr, senior vice president, global clinical development,<br \/>\n      infectious diseases and vaccines, Merck Research Laboratories. \u201cThe<br \/>\n      strong findings observed following treatment with MK-3682B are an<br \/>\n      encouraging step towards Merck\u2019s goal of developing and delivering a<br \/>\n      shorter-duration, pan-genotypic next-generation treatment regimen for<br \/>\n      more patients with chronic hepatitis C infection.\u201d\n    <\/p>\n<p>\n      <i><br \/>\n<b>C-CREST 1 <\/b><br \/>\n<\/i><br \/>\n<b>&amp;<i> 2<\/i> Part B Overview and Findings<\/b>\n    <\/p>\n<p>\n      Part B of <i>C-CREST 1<\/i> &amp; <i>2<\/i> \u2013 ongoing, open-label Phase 2<br \/>\n      clinical trials \u2013 was designed to evaluate the safety and efficacy of<br \/>\n      MK-3682B in patients with chronic HCV GT1, GT2 or GT3 infection, with or<br \/>\n      without cirrhosis. Patients with GT2 or GT3 infection received MK-3682B<br \/>\n      with or without RBV. All patients with GT1 or GT2 infection were<br \/>\n      treatment-na\u00efve. Fifty six percent (189\/337) of patients with GT3<br \/>\n      infection were treatment na\u00efve and 44 percent (148\/337) were previously<br \/>\n      treated with peginterferon\/ribavirin (RBV). The primary endpoint of the<br \/>\n      study was the proportion of patients in each treatment arm who achieved<br \/>\n      SVR12.\n    <\/p>\n<p>\n      Eight weeks of treatment with MK-3682B resulted in SVR12 rates of 95<br \/>\n      percent, 86 percent and 95 percent in GT1, GT2 and GT3 patients,<br \/>\n      respectively. A 12-week treatment duration resulted in high SVR12 rates<br \/>\n      in all genotypes (GT1, 99%; GT2, 97%; GT3, 97%). Efficacy was comparable<br \/>\n      in patients with and without cirrhosis. There were no virologic failures<br \/>\n      in the patients with GT1 or GT2 infection who received 12 weeks of<br \/>\n      MK-3682B. Efficacy results are presented in the table below. Results<br \/>\n      from Part A of <i>C-CREST 1 <\/i>&amp; <i>2<\/i> were previously reported<br \/>\n      at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fresearch-and-development-news%2Fmerck-announces-presentation-results-two-phase-2-studies-&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=The+Liver+Meeting%C2%AE+in+November+2015&amp;index=7&amp;md5=67f8f48023ce8118c5e89edad92e4c34\" rel=\"nofollow\">The<br \/>\n      Liver Meeting<sup>\u00ae<\/sup> in November 2015<\/a>.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td colspan=\"13\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"13\">\n<p class=\"bwcellpmargin\">\n            <b>Summary of SVR12 Findings<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>Population<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>N<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>MK-3682B <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>+\/- RBV<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>8 weeks<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>MK-3682B <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>+\/- RBV<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>12 weeks<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          <b>MK-3682B <\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>+\/- RBV<\/b>\n          <\/p>\n<p class=\"bwcellpmargin\">\n            <b>16 weeks<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          GT1a\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          90\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93% (39\/42)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          98% (47\/48)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8211;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          GT1b\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          86\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          98% (45\/46)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (40\/40)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          &#8211;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          GT2\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          151\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          86% (54\/63)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          97% (60\/62)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (26\/26)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          GT3*\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          337\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          95% (98\/103)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          97% (155\/159)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          96% (72\/75)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"13\">\n<p class=\"bwcellpmargin\">\n            *28 percent (29\/103), 36 percent (58\/159) and 81 percent (61\/75)<br \/>of<br \/>\n            patients with GT3 infection receiving eight, 12 or 16 weeks<br \/>of<br \/>\n            therapy, respectively, were previously treated with<br \/>\n            peginterferon\/RBV\n          <\/p>\n<p class=\"bwcellpmargin\">&nbsp;<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      Among patients who received at least one dose of MK-3682B with or<br \/>\n      without RBV, the overall most common adverse events (AEs) reported<br \/>\n      (greater than 10% incidence in either treatment arm) were headache<br \/>\n      (22%), fatigue (19%) and nausea (13%). There were two drug-related<br \/>\n      serious AEs, both considered related to RBV only. Nine patients<br \/>\n      discontinued study drug due to AEs, four of whom discontinued RBV only.<br \/>\n      One patient died due to AEs not related to the study drug.\n    <\/p>\n<p>\n      \u201cAs a scientist and physician who regularly treats patients with chronic<br \/>\n      hepatitis C, the importance of continuing to research this complex<br \/>\n      disease and its many complications is evident,\u201d said Dr. Eric Lawitz,<br \/>\n      vice president, scientific and research development, The Texas Liver<br \/>\n      Institute and clinical professor of medicine, The University of Texas<br \/>\n      Health Science Center, San Antonio. \u201cThe virologic cure rates observed<br \/>\n      in Part B of <i>C-CREST 1<\/i> &amp; <i>2<\/i> clearly demonstrate the<br \/>\n      potential for MK3 and support further study of this investigational<br \/>\n      regimen.\u201d\n    <\/p>\n<p>\n      <i><br \/>\n<b>C-SURGE<\/b><br \/>\n<\/i><br \/>\n<b> Overview and Preliminary Findings<\/b>\n    <\/p>\n<p>\n      <i>C-SURGE<\/i> is an ongoing, open-label Phase 2 clinical trial designed<br \/>\n      to evaluate MK-3682B with or without RBV in chronic HCV GT1 patients who<br \/>\n      previously failed therapy with either ledipasvir\/sofosbuvir (LDV\/SOF) or<br \/>\n      ZEPATIER\u2122 (elbasvir and grazoprevir). The study enrolled 94 patients<br \/>\n      randomized to receive 16 weeks of MK-3682B plus RBV (n=45) or 24 weeks<br \/>\n      of MK-3682B without ribavirin (n=49); one patient in the 16 week arm<br \/>\n      withdrew prior to starting treatment. Of the 93 patients who received<br \/>\n      treatment in this study, 61 percent (57\/93) had previously received 12<br \/>\n      to 24 weeks of treatment with LDV\/SOF; 15 percent (14\/93) had received 8<br \/>\n      weeks of LDV\/SOF; and 24 percent (22\/93) had received 12 weeks of<br \/>\n      ZEPATIER. A majority of patients (84%, 78\/93) had at least one baseline<br \/>\n      NS5A resistance-associated variant (RAV) at positions 28, 30, 31 or 93.\n    <\/p>\n<p>\n      Interim results from the modified full analysis set (mFAS), which<br \/>\n      excludes one patient in the 16-week arm who withdrew due to<br \/>\n      administrative reasons after receiving three doses of study medication,<br \/>\n      show all patients (43\/43) who have completed treatment with MK-3862B<br \/>\n      plus RBV for 16 weeks achieved SVR8. All patients (49\/49) in the mFAS<br \/>\n      who received MK-3682B for 24 weeks have completed treatment and remain<br \/>\n      subject to follow-up; the interim results show of those in the 24-week<br \/>\n      arm who have reached follow-up weeks four and eight, 100 percent have<br \/>\n      achieved SVR4 (38\/38) and SVR8 (30\/30), respectively. SVR12 is the<br \/>\n      primary outcome measure of this ongoing trial. Final results will be<br \/>\n      presented at a future scientific congress.\n    <\/p>\n<p>\n      Among patients who received at least one dose of MK-3682B with or<br \/>\n      without RBV, the overall most common AEs reported were fatigue (35%),<br \/>\n      headache (13%), diarrhea (9%), rash (9%) and pruritus (5%). There were<br \/>\n      no drug-related serious AEs, and no patients discontinued due to a<br \/>\n      drug-related AE.\n    <\/p>\n<p>\n      <i><br \/>\n<b>C-CREST 1 &amp; 2<\/b><br \/>\n<\/i><br \/>\n<b> Part C Overview and Findings<\/b>\n    <\/p>\n<p>\n      Part C of <i>C-CREST 1<\/i> &amp; <i>2<\/i> was designed to evaluate<br \/>\n      retreatment with MK-3682B plus RBV for 16 weeks among patients who<br \/>\n      previously failed an investigational triple-therapy regimen<br \/>\n      (MK-3682\/grazoprevir\/ruzasvir or MK-3682\/grazoprevir\/elbasvir). The<br \/>\n      study enrolled 24 patients with GT1 (n=2), GT2 (n=14) or GT3 (n=8)<br \/>\n      infection. All patients (23\/23) who completed treatment achieved SVR12.<br \/>\n      One GT2 patient discontinued treatment after a single dose due to<br \/>\n      drug-related serious AEs. Among patients who received at least one dose<br \/>\n      of MK-3682B plus RBV, the most common AEs reported (greater than 20%<br \/>\n      incidence) were headache (33%), fatigue (25%), nausea (25%), rash (21%)<br \/>\n      and insomnia (21%).\n    <\/p>\n<p>\n      <b>About MK-3682B<\/b>\n    <\/p>\n<p>\n      MK-3682B (informally referred to as MK3) is Merck\u2019s investigational<br \/>\n      triple-combination therapy in Phase 2 development for the treatment of<br \/>\n      chronic HCV infection. MK-3682B combines an HCV nucleotide analogue NS5B<br \/>\n      polymerase inhibitor (MK-3682), an HCV NS3\/4A protease inhibitor<br \/>\n      (grazoprevir, MK-5172) and an HCV NS5A inhibitor (ruzasvir, MK-8408).\n    <\/p>\n<p>\n      <b>About ZEPATIER\u2122 (elbasvir and grazoprevir) 50 mg\/100mg tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, an HCV<br \/>\n      NS5A inhibitor, and grazoprevir, an HCV NS3\/4A protease inhibitor.<br \/>\n      ZEPATIER is indicated with or without ribavirin (RBV) for treatment of<br \/>\n      chronic HCV genotypes 1 or 4 infection in adults.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER<\/b>\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3) inhibitors<br \/>\n      (e.g., atazanavir, darunavir, lopinavir, saquinavir, tipranavir,<br \/>\n      cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.g.,<br \/>\n      carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and efavirenz. If<br \/>\n      ZEPATIER is administered with RBV, healthcare professionals should refer<br \/>\n      to the prescribing information for RBV as the contraindications,<br \/>\n      warnings and precautions, adverse reactions and dosing for RBV also<br \/>\n      apply to this combination regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER if ALT levels remain persistently<br \/>\n      greater than 10 times ULN. ZEPATIER should be discontinued if ALT<br \/>\n      elevation is accompanied by signs or symptoms of liver inflammation or<br \/>\n      increasing conjugated bilirubin, alkaline phosphatase, or international<br \/>\n      normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to adverse<br \/>\n      reactions or reduced therapeutic effect due to drug interactions.<br \/>\n      Certain strong CYP3A inhibitors may increase the plasma concentration of<br \/>\n      ZEPATIER, leading to possibly clinically significant adverse reactions.<br \/>\n      Moderate CYP3A inducers may decrease the plasma concentration of<br \/>\n      ZEPATIER, leading to reduced therapeutic effect and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER with these drugs is not<br \/>\n      recommended. Physicians should consult the Prescribing Information for<br \/>\n      potential drug interactions.\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>Selected Dosage and Administration Information for ZEPATIER (elbasvir<br \/>\n      and grazoprevir)<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a single tablet taken once daily. The recommended dosing is<br \/>\n      12 or 16 weeks with or without RBV, depending on HCV genotype, prior<br \/>\n      treatment history and, for patients with genotype 1a infection, presence<br \/>\n      of certain baseline NS5A resistance-associated polymorphisms. See<br \/>\n      Prescribing Information for ZEPATIER for specific dosage regimens and<br \/>\n      durations. Refer to RBV prescribing information for RBV dosing and<br \/>\n      dosage modifications when ZEPATIER is given with RBV. To determine<br \/>\n      dosage regimen and duration of ZEPATIER for genotype 1a patients,<br \/>\n      testing for the presence of virus with one or more baseline NS5A<br \/>\n      resistance-associated polymorphisms at positions 28, 30, 31, or 93 is<br \/>\n      recommended prior to initiating treatment.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been at the forefront of the response<br \/>\n      to the HCV epidemic. Merck\u2019s chronic HCV clinical development programs<br \/>\n      have included more than 135 clinical trials in approximately 40<br \/>\n      countries and have enrolled nearly 10,000 participants. As part of our<br \/>\n      longstanding leadership in infectious diseases, Merck collaborates with<br \/>\n      the scientific and patient communities to develop and deliver innovative<br \/>\n      solutions to support people living with chronic HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=8&amp;md5=386242715781197ef0f12b4936264c88\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=Twitter&amp;index=9&amp;md5=8481e691f64f7bdeb63644903ea1cbb2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=Facebook&amp;index=10&amp;md5=9108eab0ff458a63c1d00b8c531bca01\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=YouTube&amp;index=11&amp;md5=873ffc17875f87ac2a5fe4222636f1d2\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=12&amp;md5=a3e56002a95ecadac9a44ce57b31ab09\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=13&amp;md5=d4f3b9855bd077618e6249ad5a967a25\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=14&amp;md5=6cbe5ea5fca9c9ec24c51c67e330134b\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51459658&amp;newsitemid=20161113005036&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=15&amp;md5=6e36ac6b2072e752a09b60d64eb78291\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <sup>1<\/sup> MK-3682 is an HCV nucleotide analogue NS5B polymerase<br \/>\n      inhibitor. Grazoprevir (MK-5172) is an HCV NS3\/4A protease inhibitor.<br \/>\n      Ruzasvir (MK-8408) is an HCV NS5A inhibitor.\n    <\/p>\n<p>\n      <sup>2<\/sup> Measured as HCV RNA less than 15 IU\/mL.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161113005036r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Doris Li, 908-246-5701<br \/>or<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682\/grazoprevir\/ruzasvir 1 ), the company\u2019s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Results from Part B of C-CREST 1 &amp; 2 demonstrated high rates of sustained virologic response 2 (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) in patients with chronic HCV genotype (GT) 1 or GT3 infection who received eight weeks of treatment with MK-3682B. Findings from C-CREST 1 &amp; 2 Part B also demonstrated high rates of SVR12 in GT1, GT2 and GT3-infected patients who received MK3 for 12 or 16 weeks. Findings from Part C of C-CREST 1 &amp; 2 and interim results from the ongoing C-SURGE study showed high rates of SVR12 and SVR8, respectively, in chronic HCV patients who had failed prior<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289],"class_list":["post-745303","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682\/grazoprevir\/ruzasvir 1 ), the company\u2019s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Results from Part B of C-CREST 1 &amp; 2 demonstrated high rates of sustained virologic response 2 (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) in patients with chronic HCV genotype (GT) 1 or GT3 infection who received eight weeks of treatment with MK-3682B. Findings from C-CREST 1 &amp; 2 Part B also demonstrated high rates of SVR12 in GT1, GT2 and GT3-infected patients who received MK3 for 12 or 16 weeks. Findings from Part C of C-CREST 1 &amp; 2 and interim results from the ongoing C-SURGE study showed high rates of SVR12 and SVR8, respectively, in chronic HCV patients who had failed prior\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\\\/\",\"name\":\"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-11-13T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682\/grazoprevir\/ruzasvir 1 ), the company\u2019s investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Results from Part B of C-CREST 1 &amp; 2 demonstrated high rates of sustained virologic response 2 (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) in patients with chronic HCV genotype (GT) 1 or GT3 infection who received eight weeks of treatment with MK-3682B. Findings from C-CREST 1 &amp; 2 Part B also demonstrated high rates of SVR12 in GT1, GT2 and GT3-infected patients who received MK3 for 12 or 16 weeks. Findings from Part C of C-CREST 1 &amp; 2 and interim results from the ongoing C-SURGE study showed high rates of SVR12 and SVR8, respectively, in chronic HCV patients who had failed prior","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:32+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/","name":"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-11-13T08:00:00+00:00","dateModified":"2025-11-07T06:25:32+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis-c-therapy-showing-high-rates-of-sustained-virologic-response-in-people-with-genotypes-1-2-or-3-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8776d250-2a71-4f7d-ad57-f50a6cb037f4","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Findings-for-Investigational-Triple-Combination-Chronic-Hepatitis-C-Therapy-Showing-High-Rates-of-Sustained-Virologic-BUW1A.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745303\/revisions"}],"predecessor-version":[{"id":3674712,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745303\/revisions\/3674712"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745303"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}